Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02702388 · ClinicalTrials.gov registry record · Phase 2
A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 241
- Enrollment target
NCT02702388 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 241 participants.
The verdict
NCT02702388, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 241 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily (QD) that provides comparable efficacy but has a better safety profile in participants with radioiodine-refractory differentiated thyroid cancer RR-DTC with radiographic evidence of disease progression within the prior 12 months.
Interventions
- DRUG Lenvatinib
- DRUG Lenvatinib matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2020-09-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02702388
The ClinicalTrials.gov registry entry for NCT02702388 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenvatinib is the first listed.
NCT02702388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02702388 about?
NCT02702388 is a clinical study titled "A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile". This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily (QD) that provides comparable efficacy but has a better safety profile...
What is the current status of trial NCT02702388?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 241 participants. The study started on 2017-06-08. Estimated completion is 2020-09-10.
What interventions are being tested in trial NCT02702388?
The interventions under investigation include: Lenvatinib (DRUG), Lenvatinib matching placebo (DRUG).
Who is sponsoring clinical trial NCT02702388?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.